生物制药公司Nimbus Therapeutics今日宣布，已与全球医药巨头礼来（Eli Lilly）签署一项针对新型口服肥胖症疗法的研发合作与许可协议。该合作将结合Nimbus在创新药物发现方面的专长与礼来在代谢疾病领域的开发及商业化能力，共同推进一款潜在重磅疗法的研发进程。
根据协议条款，Nimbus将主导早期研究活动，礼来则拥有在特定阶段行使独家许可选择权的权利。协议达成后，Nimbus可获得一笔预付款，并有资格获得基于研发、注册和商业里程碑的后续款项，以及产品上市后的分级销售分成。双方未披露具体的财务细节。
此次合作聚焦于口服小分子疗法，旨在解决当前肥胖症治疗领域中未被满足的医疗需求。若研发成功，该疗法有望为全球数百万肥胖患者提供一种新的、便捷的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.